News

Neural stem cells may fight chemo brain


 

Lab rat

Photo by Janet Stevens

Human neural stem cell treatments are showing promise for reversing learning and memory deficits after chemotherapy, according to an article in Cancer Research.

Investigators found that transplanting stem cells in rats a week after they completed a series of chemotherapy sessions restored a range of cognitive functions, as

measured a month later via behavioral testing.

In contrast, animals that did not receive stem cells showed significant learning and memory impairment.

“Our findings provide the first solid evidence that transplantation of human neural stem cells can be used to reverse chemotherapeutic-induced damage of healthy tissue in the brain,” said study author Charles Limoli, PhD, of the University of California, Irvine.

For this study, Dr Limoli and his colleagues transplanted adult neural stem cells into the brains of rats that had received cyclophosphamide.

The cells migrated throughout the hippocampus, where they survived and differentiated into multiple neural cell types. Additionally, these cells triggered the secretion of neurotrophic growth factors that helped rebuild wounded neurons.

The investigators also found that engrafted cells protected the host neurons, thereby preventing the loss or promoting the repair of damaged neurons and their finer structural elements, referred to as dendritic spines.

“This research suggests that stem cell therapies may one day be implemented in the clinic to provide relief to patients suffering from cognitive impairments incurred as a result of their cancer treatments,” Dr Limoli said. “While much work remains, a clinical trial analyzing the safety of such approaches may be possible within a few years.”

Recommended Reading

CRT may pose long-term risk of hormone deficiencies
MDedge Hematology and Oncology
Cancer patients rarely make inappropriate requests, study shows
MDedge Hematology and Oncology
Leukemia, lymphoma cause more distress in young adults
MDedge Hematology and Oncology
Signs may predict death in cancer patients
MDedge Hematology and Oncology
Approved TKI could treat drug-resistant CML, ALL
MDedge Hematology and Oncology
Computer model simulates blood development
MDedge Hematology and Oncology
Though costly, blood cancer drugs appear cost-effective
MDedge Hematology and Oncology
Vaccine gets orphan designation for ATLL
MDedge Hematology and Oncology
Risk of HBV reactivation ‘underappreciated’
MDedge Hematology and Oncology
Aggressiveness of CLL linked to genetic variability
MDedge Hematology and Oncology